Navigation Links
Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
Date:6/23/2008

MOUNTAIN VIEW, Calif., June 23 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it will present results of its Phase 2a clinical trial of Staccato(R) loxapine (AZ-104) for the treatment of migraine headache at the 50th Annual Scientific Meeting of the American Headache Society, which being held at the Marriott Boston Copley Place in Boston, MA. The oral platform abstract presentation, "Inhaled Loxapine, a Dopamine Antagonist, Reduces Headache Pain in Patients Having an Acute Migraine Attack", is scheduled for Friday, June 27, 2008 at 10:55 a.m. Eastern Time, and will be presented in University Hall. AZ-104 is a lower dose version of AZ-004, which is in Phase 3 clinical development for the treatment of acute agitation in patients with schizophrenia or bipolar disorder.

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing and has completed the enrollment of its first Phase 3 clinical trial. AZ-001 (Staccato prochlorperazine) for the acute tre
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
2. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
3. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
4. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
7. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
8. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
9. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
10. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
11. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009).../--ChindexInternational,Inc.,("Chindex")(Nasdaq: C...,healthcareproductsandservicesinthePeople,sRepubli...e21stAnnualPiperJaffray,"Unplugged"HealthCareConfe...Hotel. , Managementiscurrentlyscheduledtopres...-on-onemeetingsthroughouttheday.Awebcast,ofthepres...
(Date:11/24/2009)...stCall/--Endologix,Inc.(Nasdaq: ELGX ),developerof...uncedtodaythatithasfiledamotiontostay,ordiscontinu...ghtagainstitinOctober2009byCook,Inc.Themotionwasfi...diana. ,, Endologixhasrequestedthatthestayremai...ice(USPTO)conductsproceedingstore-examinethetwopat...
(Date:11/24/2009)...rstCall/--Vermillion,Inc.(VRML)(PinkSheets:VRMLQ)a...isclosureStatementtoday,November24,2009,withtheUni...hearingtoconsiderapprovaloftheDisclosureStatementi...gontheconfirmationofthePlanscheduledforJanuary7,20...nfull.ThePlanisexpected,ifapproved,toallowholderso...
Breaking Medicine Technology:Chindex International to Present at Piper Jaffray Health Care Conference 2Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2Vermillion Files Plan of Reorganization 2Vermillion Files Plan of Reorganization 3Indiana Drug Card to Provide Free Drug Cards to Residents 53014 1Indiana Drug Card to Provide Free Drug Cards to Residents 53014 2New BioTrends Report Explores Anticipated Treatment Pattern Shifts Expected with the Proposed Bundled Payment Structure Planned for 2011 53012 1New BioTrends Report Explores Anticipated Treatment Pattern Shifts Expected with the Proposed Bundled Payment Structure Planned for 2011 53012 2Urine Test for Chlamydia Shown Effective in Men 53011 1
...aunch Progress and Adlea R...all Today at 11:30 am ET, SOUTH SAN FRANCISCO, Ca...nced today that the company will restructure,opera...t development to,accelerate its transition to a sp...e company also provided updates on Zingo launch pr...
...d That Multaq(R) (Dronedarone) Decreased the Risk,...ion or Atrial Flutter,Already Adequately Treated b...oc analysis of the data from the ATHENA study,were...ion of the European,Society of Cardiology congress...he landmark ATHENA study have shown that the inves...
Other Medicine Technology:Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 2Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 3Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 5Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5
(Date:11/26/2009)... Research Triangle Dental (RTDe...North Carolina, today announced the expansion of i...MINEER Dentist, Dr. Doug Macmillan. , ...angle Dental is pleased to announce that Dr. Doug ...ently completed an additional advanced training se...
(Date:11/25/2009)..., EMERYVILLE,Calif.,Nov.25/PRNewswire-FirstCall/--...uncedthatthecompanywillhosttwoinvestoreventsinDece...-9:00a.m.CT/10:00a.m.ET ,, Principalinvestiga...omibinrelapsedand/orrefractorymultiplemyeloma,asfe...ualMeetingandExpositioninNewOrleans,LA.Theteleconf...
(Date:11/25/2009)..., LOSANGELES,Nov.25/PRNewswire-USNewswire/--TheBla...stodetermineexecutiveleadershipfor2010. ,, Then...pecialtiesinpublicpolicy,law,finance,governmenthea...TheBoardalsocomesfromawiderangeofpersonalbackgroun...somelivingwithHIVthemselves,andrepresentingmultipl...
(Date:11/25/2009)...fortuitous discovery that grew out of a collaborat...tentially offer hope to the nearly 10 million Amer... , Also known as hardening of the arteries, ...irculatory problem in which narrowed arteries redu...dered a red flag for vascular disease, heart attac...
(Date:11/25/2009)...e, forgetfulness could lead mothers to overlook ne...v. 25 (HealthDay News) -- A mother,s depression ca... found. , Their six-month study of 262 black mo... mothers had more depressive symptoms had more fre...ith fewer depressive symptoms had less frequent as...
Breaking Medicine News(10 mins):Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2Health News:Black AIDS Institute Announces 2010 Board Election Results 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Mom's Depression May Worsen Child's Asthma 2
... A new drug, ADDERALL XR? has been found to improv...ntion in young adults with attention-deficit/hyper...een presented at the 18th Annual U.S. Psychiatric ... Accidents are the leading cause of death until ag...
... Recent research findings suggest that reflecting ...chological responses to stress at low levels. S...ession of a broad array of mental and physical hea...d in the November issue of the journal Psychologic...
... An article published in the November issue of the...kah or a water pipe has the same effect on the gum...al disease and are equally devastating as far as t... that the impact of the water pipe is largely simi...
... Taxotere which is the choice of drug for patients...ve their choice to choose this drug as the Scottis...he drug is very expensive and it does not have muc...ry good effect in reducing tumor burden in these p...
... Several religious luminaries have expressed conce...ion that has resulted in a sharp decline in girl p...nt is believed to put an end to the practice of ge...the Art of Living Foundation spiritual head Sri Sr...
... A study in the US shows that exposure to on-scree...r in determining whether young people will take up...researchers from the Dartmouth Medical School (DMS...king accounted for smoking initiation among over o...
Other Medicine News:Health News:New Drug Found To Improve Driving Performance In Young Adults With ADHD 2Health News:Imbalance In Gender Ratio Addressed By Religious Leaders 2
DIX Foreign Body Spud
...age lens is made from MMA/VP material and has a hi...th the base curve and total diameter as specified ...ower range of -30.00DS to +30.00DS,Simplon Ba...d therapeutic applications including the controlle...
Ellis Needles
Bandage
Medicine Products: